Tecuro is working on a breakthrough technology to treat and prevent urinary tract infection. Alongside Tecuro’s friends and family, SymbioSwiss and investiere-investors, two leading business angel clubs based in Suisse romande participated in this financing round. Namely the Romandie section of Business Angels Switzerland (BAS) and Cercle des Investisseurs de Genève (CIG).
The Lucerne-based company is developing a hygienic panty liner that both treats and prevents recurrent urinary tract infections - a widespread problem that 3% of women worldwide suffer from recurrently. Tecuro's product is the only medicinal alternative to antibiotics to date, making it a welcome form of treatment and a potentially lucrative venture in a $3 billion market.
Over the last couple of months, Tecuro has achieved numerous product development milestones —thus continuously reducing the company’s technological risk— and has recently commenced designing the production process for its hygienic pad. The Tecuro team is led by Jean-Jacques Becciolini, a serial entrepreneur with a successful exit under his belt, who has built up an experienced team with strong ties to extremely relevant industry partners such as Johnson & Johnson, Kimberley Clark, SCA, Procter & Gamble and more.
“We thank investiere for trusting Tecuro’s team and giving the company a leg up in its first investment round,” Becciolini states.